The active substance is supplied as a non-sterile, single-component crystalline powder for further pharmaceutical processing. It is defined by CAS 103-90-2, chemical name N-(4-hydroxyphenyl)acetamide, empirical formula C8H9NO2, and relative molecular mass 151.16 g/mol. The material belongs to the para-aminophenol derivatives and is an analgesic and antipyretic, not a salicylate or a propionic acid-class non-steroidal anti-inflammatory drug. Under Ph. Eur. 2.2.14, the crystalline form displays a melting range of 168–172 °C; the pKa is approximately 9.5 at 25 °C, and the aqueous solubility is approximately 14 mg/mL at 25 °C. These values are relevant to dissolution in gastrointestinal fluids, injectable co-solvent selection, and premix leaching. No proprietary model code is attached to the product; the material is identified in quality files by the non-proprietary monograph designation and the relevant marketing-authorisation dossier code. The substance is manufactured under a veterinary medicinal product quality system, with documentation suitable for tablets, injections, capsules, powders, granules, premix, and solutions.

The product is packaged in double polyethylene liners inside fibre drums or food-grade aluminium laminate bags; typical net weights are 25 kg and 50 kg, although the exact configuration is defined by the destination market and the validated charging line. A quality agreement between the API manufacturer and the dosage-form manufacturer specifies whether the material is released for oral, parenteral, or feed-directed processing. Microbial enumeration and endotoxin requirements increase as the intended route moves from feed premix to injectable solution.

Because the molecule is not an acid and not an NSAID, the clinical toxicological behaviour in companion animals differs from that of flunixin meglumine, meloxicam, and ketoprofen. Feline species should not receive paracetamol because of limited glucuronidation capacity; canine administration requires strict dosage control because of the formation of the reactive metabolite N-acetyl-p-benzoquinone imine. For food-producing species, regulatory acceptance must be verified against the national positive list or maximum-residue-limit framework before the premix or solution form is used.

What distinguishes a veterinary-grade paracetamol API from a human monograph product?

At the molecular level, no distinction exists between the human grade and the veterinary grade. Both are described by Ph. Eur. 0049 or the USP Acetaminophen monograph, and the core assay, related-substances, loss-on-drying, sulphated-ash, and residual-solvent requirements are aligned. The difference is operational and regulatory: veterinary API is released for animals, meaning that contamination-control limits, documentation, and distribution are managed under Regulation (EU) 2019/6 or the US FDA Center for Veterinary Medicine expectations, rather than human marketing-authorisation requirements. The same factory may manufacture both grades, but the veterinary batch is segregated in packaging and labelling to prevent human-supply-chain diversion. For active substances intended for food-producing animals, residue and withdrawal-period considerations are appended to the release file even though the monographed chemistry remains unchanged.

During regulatory file assembly, the veterinary dossier may contain target-animal safety data, species-specific metabolism data, and field trial evidence generated in accordance with VICH guidelines. The impurity profile is still controlled against the pharmacopoeial monograph; no reduction in chemical purity is permitted solely because the product is veterinary. The operational boundary is that veterinary-grade paracetamol is not automatically acceptable for human use unless the manufacturing site holds the corresponding human marketing authorisation and the batch has been released against the human monograph in the intended destination market.

Particle-size and powder-flow parameters for direct compression and wet granulation.

For solid oral dosage forms, the material is milled or classified to meet release criteria defined by laser diffraction under Ph. Eur. 2.9.31. A typical powder-grade specification may include D90 ≤ 250 µm, D50 ≤ 100 µm, and D10 ≥ 10 µm, but the exact targets are adjusted to the downstream tableting route. Bulk density and tapped density are measured according to Ph. Eur. 2.9.34; Hausner ratio and Carr index are derived from these data. Paracetamol crystals display relatively poor compactability and a tendency to fragment under compaction. When the dusted blend is compressed on a rotary tablet press at 30–80 rpm, high drug loads above 70 % w/w may produce capping and lamination, particularly when moisture content is below 0.2 % or when the lubricant mixing time exceeds 5 min in a bin blender.

Direct compression without granulation is limited by the crystal’s fragmentation behaviour. Published data for this specific configuration is limited; formulators routinely overcome the deficiency by using wet granulation in a high-shear granulator with impeller speeds of 200–400 rpm and binder addition of 5–15 % w/w, or by using a roller compactor for dry granulation. The granulated intermediate for tablets should have a loss on drying of 1.0–3.0 % before lubrication and compression to avoid punch sticking. For capsules, the same powder or granule is filled into hard gelatin or hydroxypropyl methylcellulose shells; flowability is improved with colloidal silicon dioxide at 0.1–0.5 % w/w, and segregation is controlled by matching the active particle size to the lactose or dicalcium phosphate filler.

Encapsulation of the veterinary API requires a fill-weight uniformity study under Ph. Eur. 2.9.5; capsules are usually prepared from a granulated premix rather than directly from raw crystals because of post-hopper flow variability. Powders for oral administration are dry-blended in a diffusion mixer such as a V-blender or container blender for 15–30 min, then filled into sachets; the acceptance limit for blend uniformity is typically 90–110 % of the target assay with an RSD not exceeding 5.0 %. Granules for feed application are produced by adsorption onto a carrier such as lactose monohydrate or wheat middlings, with subsequent drying to a final moisture content below 5.0 % to prevent microbial growth and clumping during storage at 25 °C / 60 % RH.

When the API is formulated into injectable solutions, what limits apply beyond oral-grade controls?

In aqueous injection vehicles, the primary degradation pathway is hydrolysis of the amide bond to 4-aminophenol and acetic acid. The hydrolysis rate is pH-dependent; maximum solution stability is generally observed in the range 5.0–6.0. Terminal sterilisation by autoclave at 121 °C for 15 min imposes additional thermal stress and may increase free 4-aminophenol unless the solution is nitrogen-sparged and protected from oxygen. Therefore, the injection-grade active substance is typically subject to tighter microbial enumeration and endotoxin controls than the oral grade. Bacterial endotoxin testing is performed according to Ph. Eur. 2.6.14 or USP 85; the acceptance limit is derived from the maximum species-specific dose and the finished-product route of administration, and is not a universal monograph number.

Injectable solutions for dogs and other non-food animals may include co-solvents such as propylene glycol or ethanol to maintain the active concentration; the active substance should be dissolved under inert gas and protected from light because photolytic degradation can contribute to colour formation. The product itself is supplied non-sterile; therefore terminal sterilisation or aseptic filtration of the finished solution remains the responsibility of the dosage-form manufacturer. Filtration through a 0.22 µm membrane does not remove endotoxin; endotoxin control must be achieved in the API and excipients before compounding.

In feed-mill and drinking-water applications, dispersion mechanics and water-matrix stability dominate the design of the dosage form. For premix, the active substance is diluted into a carrier at a defined inclusion rate, mixed in a horizontal ribbon blender or paddle mixer, and then incorporated into complete feed at a target final concentration. The blend must resist segregation during pneumatic conveying; a carrier particle size below 500 µm and a moisture content below 5.0 % limit bridging in feed bins. In drinking-water solutions, the active concentration must remain within 90–110 % of the labelled amount for the prescribed medication period; pH drift and exposure to copper or iron pipes can accelerate 4-aminophenol formation, so water-quality testing is part of the stability protocol. These formulations are not interchangeable with the injectable or tablet presentations; the dissolution and distribution profile in feed is determined by carrier desorption and mixing efficiency, not by the disintegration mechanism of a compressed tablet.

Dissolution, compactability, and batch-to-batch consistency under 21 CFR Part 211

Batch release for the veterinary API includes demonstration of identity, assay, related substances, loss on drying, residue on ignition, residual solvents, and microbial quality. The testing is executed under a pharmaceutical quality system aligned with 21 CFR 211 and Ph. Eur. general texts or ICH Q7, depending on the destination market. For tablet and capsule presentations, finished-product dissolution testing is performed using USP apparatus 2 or Ph. Eur. 2.9.3; typical media include phosphate buffer at pH 5.8 or simulated gastric fluid without enzymes, with sampling time points at 15, 30, and 45 min. The compactability of the granulated material is assessed by tablet hardness, friability according to Ph. Eur. 2.9.7, and disintegration time according to Ph. Eur. 2.9.1.

Batch-to-batch consistency is monitored through control charts for particle size, bulk density, and dissolution of the finished product. Any shift in the D50 of the active substance above 10 % relative to the qualification batch requires revalidation of the blending and compression steps. Punch sticking on long production runs is a known failure mode; the use of magnesium stearate at 0.25–0.75 % w/w with a mixing time not exceeding 5 min balances lubrication against delayed dissolution. The active substance may be sensitive to moisture above 60 % RH; therefore, storage is specified in the manufacturer’s approved label, and pre-drying may be required before direct compression if the water content exceeds the validated range.